Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate)

About Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate)

Syn-Ake is a synthetic dipeptide designed to mimic Waglerin-1, a neurotoxin from temple viper venom that antagonises the nicotinic acetylcholine receptor at the neuromuscular junction. The intended cosmetic effect follows from that mechanism: less acetylcholine signalling means less muscle contraction and softer expression lines. It is a patented ingredient, originally from Pentapharm and now marketed by DSM-Firmenich. The reason its evidence tier is the lowest in this batch is straightforward — a literature search on 2026-08-04 returned no independent peer-reviewed trial. The efficacy claims trace back to the manufacturer's own published testing and to reseller material that repeats it. That does not make the compound ineffective, but it does mean nobody outside the supply chain has verified the claims, which is a materially different situation from Matrixyl's independent placebo-controlled trial. At around 496 Da it is small enough that penetration is less of an obstacle than for Argireline.

Key Benefits

• Small enough (~496 Da) that skin penetration is less limiting than for larger peptides
• Defined mechanism — nicotinic acetylcholine receptor antagonism
• Does not require injection

Category Ratings

How to Take

Common Side Effects

• Poorly characterised — no independent published safety evaluation
• Contact irritation or sensitivity possible
• Not evaluated for injection

Legal & Regulatory Status

Sold as a cosmetic ingredient and as a research chemical; not a drug and not FDA-approved. No independent peer-reviewed efficacy or safety trial was located.

Safety and regulatory details for FDA-approved compounds are drawn from the official product label via openFDA; clinical development status reflects ClinicalTrials.gov. This information is provided for research reference, is not endorsed by the FDA, and may not be complete or current.

Research & Sources

• Usage of synthetic peptides in cosmetics — class context for neuromuscular cosmetic peptides (PMC8400021)

Sources are selected for reliability (peer-reviewed literature, openFDA, ClinicalTrials.gov) but this is a research summary, not medical advice, and may not be exhaustive.